EUCTR2010-018383-16-HU进行中（未招募）不适用
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus - Celestial 47
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are included in the study if all of the following criteria are met:
- •(a) The patient is a man or woman between 18 and 70 years of age with an established diagnosis of SLE as defined by ACR Classification Revised Criteria. The diagnosis is fulfilled provided that at least 4 criteria are met.
- •(b) The patient has a positive test for ANA at screening (titer must be at least 1:80 [by human epithelial cell tumor line (HEp 2) ANA assay]) and/or a positive test for anti dsDNA Ab at screening (value must be 30 IU/mL or more by ELISA).
- •(c) Written informed consent is obtained.
- •(d) Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of contraception, and must agree to continued use of this method for the duration of the study and for 30 days after discontinuation of study drug treatment. Acceptable methods of contraception include barrier method with spermicide, abstinence, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- •(e) The patient has a clinical SLEDAI 2K score of at least 6 points during screening. A clinical SLEDAI 2K score is the calculated score without inclusion of the points that may be contributed by having a positive titer for anti dsDNA Ab or decreased serum complement levels.
- •(f) The patient does not have an A” score on the BILAG 2004 scale.
- •(g) If the patient is using oral corticosteroids, the weekly cumulative dose must not exceed 80 mg of prednisone equivalent; the weekly dose must be stable over the 4 weeks preceding the 1st dose of study drug.
- •(h) If the patient is using antimalarials, methotrexate, leflunomide, mycophenolate mofetil, or azathioprine, the start date must be at least 3 months prior to the 1st dose of study drug, and the daily dose must be stable over the 4 weeks preceding the 1st dose of study drug.
- •(i) If the patient is not currently using corticosteroids, antimalarials, methotrexate, mycophenolate mofetil, or azathioprine, the last dose (in case of previous use) must be at least 4 weeks prior to the 1st dose of study drug. For leflunomide, the stop date must be at least 8 weeks before the 1st dose of study drug, unless an adequate cholestyramine washout has been completed.
- •(j) The patient must be willing and able to comply with study restrictions, to remain at the study center for the required duration during each study visit, and to return to the study center for the final assessment as specified in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 216
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- •(a) The patient has been treated with intramuscular or iv pulse steroids (ie, 250 to 1000 mg iv total daily dose of methylprednisolone) within 4 weeks of the 1st dose of study drug. The use of intra articular steroids may be allowed after consultation with the medical expert.
- •(b) The patient has received tacrolimus, cyclosporine A, or intravenous immunoglobulins (IVIG) within 3 months of the 1st dose of study drug.
- •(c) The patient has received cyclophosphamide within 12 months prior to the 1st dose of study drug.
- •(d) The patient has been treated for SLE with agents such as fusion proteins, therapeutic proteins, or monoclonal antibodies or antibody fragments, within 12 months of the 1st dose of study drug.
- •(e) The patient has received B cell depleting agents such as rituximab and has not yet normalized the B cell count (ie, CD20+ B cell count is less than 200 and the absolute lymphocyte count [ALC] is less than 1500/µL).
- •(f) The patient has New York Heart Association (NYHA) Class III or IV congestive heart failure.
- •(g) The patient has severe active lupus nephritis or cerebritis.
- •(h1) The patient has an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m2 (via Modification of Diet in Renal Disease [MDRD] equation).
- •(i) The patient has an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value greater than 2 times the upper limit of normal (ULN) or a total bilirubin level greater than 1.5 times the ULN.
- •(j) The patient has a planned immunization with a live or live attenuated vaccine within 3 months prior to administration of the 1st dose of study drug and for 3 months after administration of the last dose of study drug.
- •(k1) The patient has any clinically significant abnormalities on the 12-lead ECG that are not related to SLE, as determined by the investigator. Patients with stable ECG changes without evidence of active cardiovascular disease may participate at the discretion of the investigator and medical monitor.
- •(l) The patient has an ongoing active systemic infection requiring treatment or a history of severe infection, such as hepatitis or pneumonia, in the 3 months prior to administration of the 1st dose of study drug. Less severe infections in the 3 months prior to administration of the 1st dose of study drug are permitted at the discretion of the investigator and medical monitor.
- •(m1) The patient has any concomitant medical condition unrelated to SLE that may interfere with his or her safety or with evaluation of the study drug, as
- •determined by the investigator.
- •(n) The patient has a history of a medical condition other than SLE that has required treatment with steroids in excess of 80 mg of prednisone equivalent/week within 6 months of the 1st dose of study drug.
- •(o) The patient has a positive test result for HBsAg or HCV Ab.
- •(p) The patient has a known positive history of antibodies to human immunodeficiency virus (HIV) or HIV disease.
- •(q) The patient has a history of alcohol or substance dependence or abuse (with the exception of nicotine), according to the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, Fourth Edition, Text Revision (DSM IV TR), within 3 months of the screening visit or has current substance abuse.
- •(r) The patient has a history of severe allergic reactions to or hypersensitivity to any component of the study drug or plac
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Subjects with Major Depressive DisorderMedDRA version: 18.0Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2015-000306-18-FIMinerva Neurosciences, Inc.80
未知
3 期
A Phase III Study of SM-13496 in Patients with Bipolar I Depression.JPRN-jRCT2080222269Sumitomo Dainippon Pharma Co., Ltd.501
进行中（未招募）
不适用
This is a multinational study comparing the efficacy and safety of two medicines , solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder.MedDRA version: 17.1Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 100000004857Overactive BladderEUCTR2012-005735-91-EEAstellas Pharma Europe B.V.7,000
已完成
Unknown
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Plant-based extract mixture on Hangover ImprovementMental and behavioural disordersKCT0008402H Plus Yangji Hospital80
进行中（未招募）
不适用
This is a multinational study comparing the efficacy and safety of two medicines , solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder.Overactive BladderEUCTR2012-005735-91-LVAstellas Pharma Europe B.V.4,500